Imatinib mesylate (GleevecTM), a tyrosine kinase inhibitor, is very effective in treating chronic myeloid leukemia and show good efficacy for the treatment of advanced gastrointestinal tumors with positive c-kit expression [24]. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.